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The adjuvant treatments dependent on ﬁndings from lumpectomy and SLN specimens. The aim of this study is to determine
the prevalence of addiction disease in patient with micrometastatic sentinel node and assess potential predictors factors.
Materials and methods. Retrospective analysis of 1213 patients in the University Hospital of Vigo and Pontevedra with breast
cancer in stage T1–T2 selecting those with micrometastases in the sentinel lymph node biopsy (SLNB), between January 2007
and December 2011. Excluding subjects with chemotherapy neoadjuvant, surgery and/or radiotherapy and no migration of the
radiotracer.
Results. We revised 1213 SLNB: 254 (20.9%) macrometastases followed by ALND (pN1a1b2), 101 micrometastases (8.32%), 38 (3.1%)
isolated cells (pN0 (i+)), 820 (67.6%) negative (pN0(i−)). Micrometastases (101) in SLNB: 25 (24.7%) patients were not performed
ALND, of these 13 received radiotherapy axillaries chains. All without relapse of disease and free of side effects from RT. 76
(75.24%) was performed ALND: 11(21%) with macrometastases, 2 (8%) micrometastases. 4 (3%) isolated tumor cells and 63 (68%)
non metastases. Mean follow-up 32 months (range 5–59). 76.3% Grades 2–3. Her2 negative 63.3%. Invasive ductal carcinoma and
hormone receptor positive majority. Received hormone therapy 92% and chemotherapy 73.6%. 2 patients developed metastases,
4 deaths, 1 per progression.
Conclusion. In our series, the rate of additional axillary disease in patients with micrometastases in SLNB is low. However 14% have
disease>2mm. A selected subgroup of patients N1mi, could be avoided ALND without deteriorating its forecast. The decision of
ALND should be individualized considering multiple factors. We did not ﬁnd association between additional disease and size,
grade, Ki67/Her2 status or histological type.
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Objective. Evaluate toxicity, aesthetic result and outcome in the ﬁrst 294 breast cancer patients (pts) treated with hypofractionated
radiotherapy (HFRT) scheme at 2 years of follow up.
Material and methods. Clinical records of 294 breast cancer pts receiving postoperative HPRT after conservative surgery pts had
been evaluated. Age: mean 57.26 years (range 30–80). Tumor location: 54.08% (158) of the pts on the right breast and 45.92%
(136) on the left. Surgical treatment: lumpectomy+sentinel lymph node technique (181 pts, 61.56%), quandrantectomy+axillary
dissection (60 pts, 20.40%), and lumpectomy+axillary dissection (53 pts, 18.04%). Histology: CDI (94.89%). Tumor size: 1.39 cm
(range 0.4–5.8). Histological grade: GI 29.25%, G2 40.81% and G3 29.94%. Resection margins: 18 pts (6.12%) with positive margins.
Hormone receptors: (−) in 6.46%. HER-2: (−) in 11.22%. Sentinel lymph node: (+) in 1.70%. Isolated axillary nodes: mean 12.5 (range
1–24). Positive 1.02 (range 0–2). Stage: I 70.06%, II 27.55%, and III 2.39%. HFRT schedule: Breast: 40.5Gy in 15 fractions of 2.7Gy.
Boost: 103 pts (35.03%) received no boost, 191 (64.97%) received 13.5Gy/5 fr. Adjuvant chemotherapy: 52.38%. Hormone therapy:
58.87%. Follow-up schedule: weekly based during HPRT, 1 month after its completion and, later, every three months.
Results. 77 pts (26.19%) developed radiodermitis. 64 Grade I and 13 Grade II. Mean dose of radiodermitis appearance: 34.92Gy
(range 13.5–46.5). At 6 months, 17 pts (5.78%) had a slight residual hyperpigmentation in the treated area. At 1 year only 5 pts
(1.70%) presented it. At 2 years 2 local relapse have occurred and all remaining pts had a normal-looking skin.
Conclusions. Toxicity and local control of HFRT are equivalent to that obtained with conventional fractionation. Besides, HFRT
reduces total time of treatment and a decrease in the waiting list is achieved.
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Introduction. If we review literature, radiation-related complication rates seem to be higher among women undergoing
expander/implant reconstruction, irrespective of when RT is given in relation to surgery. The late results of the complex tissue
changes induced by RT are capsular contracture, impaired skin healing, implant rupture, malpositioning or extrusion. However,
not all studies indicate poor cosmetic/aesthetic outcomes or satisfaction in women who undergo immediate reconstruction
followed by RT. In general, if there is indication of administering adjuvant radiotherapy, delayed reconstruction is preferred. But
in some cases this is impossible, either because the indication for postoperative radiation therapy arises after surgery, either by
explicit request of the patient.
Objective. To show our experience in treating patients after breast reconstruction with a breast expander.
